The Cardioprotective Potential of von Willebrand Disease in Ischemic Heart Disease

Author:

Mihyawi Nawfal1,Ajmal Muhammad2,Fath Ayman R.1,Bhattarai Bikash3,Yeneneh Beeletsega4

Affiliation:

1. 1 Internal Medicine Department, Creighton University, Phoenix, Arizona

2. 2 Cardiology Department, University of Arizona, Tucson, Arizona

3. 3 Research Department, Valleywise Health, Phoenix, Arizona

4. 4 Cardiology Department, Creighton University, Phoenix, Arizona

Abstract

von Willebrand factor (vWF) aids coagulation at sites of vessel injury. Elevated vWF levels have been associated with an increased risk of ischemic heart disease (IHD); however, it is unclear whether vWF deficiency, seen in patients with von Willebrand disease (vWD), protects people against IHD. We determined and compared the prevalence and risk of IHD in patients with versus without vWD by using data from the National Inpatient Sample (2009–2014), excluding patients younger than 18 and older than 75 years. The primary outcome was the odds ratio (OR) of IHD in patients with versus without vWD. Secondary outcomes were major medical comorbidities and demographic characteristics in patients with vWD. Of 224,475,443 weighted hospital-discharge samples, we identified 82,809 patients with a vWD diagnosis. The odds of IHD were lower in patients with vWD than in those without (OR=0.54; 95% CI, 0.52–0.56). After multivariable logistic regression analysis and adjustment for age, sex, and typical IHD risk factors (hypertension, smoking, diabetes, hyperlipidemia, chronic kidney disease, obesity, and family history of IHD), the likelihood of IHD remained lower in patients with vWD than in patients without (OR=0.65; 95% CI, 0.63–0.67). Our study shows that vWF deficiency, as seen in patients with vWD, is associated with a decreased prevalence of IHD. Further investigation may confirm these findings.

Publisher

Texas Heart Institute Journal

Subject

Cardiology and Cardiovascular Medicine

Reference20 articles.

1. Heart disease and stroke statistics-2020 update: a report from the American Heart Association;Virani;Circulation,2020

2. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines [published errata appear in Circulation 2019;140(11):e649–50, Circulation 2020;141(14):e60, and Circulation 2020;141(16):e774];Arnett;Circulation,2019

3. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions;Virmani;Arterioscler Thromb Vasc Biol,2000

4. Detection of von Willebrand factor and tissue factor in platelets-fibrin rich coronary thrombi in acute myocardial infarction;Yamashita;Am J Cardiol,2006

5. NHLBI von Willebrand disease expert panel. The diagnosis, evaluation, and management of von Willebrand disease

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3